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Literature search 
1996 – March 2016 
Overall:  
from 0%-29% 
6%-11% 
0%-10% 
0%-18% 
5% 
0% 
0% 
0% 
30% 
21% 
0% 
Sample sizes: 11 to 2802 
(infection and colonization) 
“carbapenem-resistant OR carbapenemase OR carbapenem-resistant Enterobacteriaceae  
AND community OR outpatient OR community-associated OR community-acquired OR community-onset” 
Most studies provided no/partial data about healthcare exposure 
Only 4 studies performed genotypic analysis for carbapenemase genes   
  Community-Onset infection (COI)  
Healthcare-associated: 
 ≤  48/72 hrs after admission 
 ≥ 1 healthcare risk factors: 
- hospitalization 
- surgery 
- dialysis 
- LTCF stay 
- presence of an invasive device 
If none of them 
“Genuine” 
Community-Associated  
infection (CAI)  last  12 months 
Infection/Colonization 
in the community 
Household 
2008-2012: 305 CRE 
COI=60% 
CAI=6% 
2012-2013: 102 CRE 
COI=65%, CAI=11% 
Grundmann et al., LID, Feb 2017 
70.6% 39.7% 
Nov 2013 – Apr 2014 
455 hospitals 
36 countries 
44.6% 10.9% 36.5% 0.08% 
18.2% 26.0% 55.8% 
RANKING 
1. KPC:                 42.4% 
2. OXA-48-like:   38.1% 
3. NDM:               12.2% 
4. VIM:                 7.3% 
Trepanier P et al., J Antimicrob Chemother, 2017 
Criteria: 
HAI: inpatients > 48 hrs 
COI: outpatients or inpatients ≤48 hrs 
Alice Y. Guh et al., JAMA, October 2015 
Hospital CPE are the same found in outpatients (?) 
Transmission of hospital CPE to healthy people in community? 
Park SO et al., Open Forum Infect Dis, 2016 
≤72 hrs 
no hosp. last 30 days 
Proportion of HAI and COI were positively correlated 
Huang TD et al., Eurosurv, 2017 
(serving GPs for outpatients care) 
Epidemiological link between the 
two healthcare sectors 
24 
10 
OXA-48-Kp: ST11, ST15, ST405, ST788 
(De Laveleye et al., EJCMID,  2017) 
CMI, 2012 
125 KPC-Kp carriers  
during hospitalization 
Before discharge 
Some dropped out/died 
44% 50% 
34% 32% 33% 
Risk factors 
- Low functional status 
- High Charlson index 
- Invasive device 
- [antibiotic use, NS] 
82 index patients (72 Ec; 10 Kp) 
112 hospital contacts 
96 household contacts 
28% 
ST131 
Transmission rates in hospital 
- 4.5% ESBL-E.  coli 
(5.6/1000 exposure days) 
- 8.3% ESBL-K.  pneumoniae 
(13.9/1000 exposure days) 
Transmission rates at home 
- 23% ESBL-E.  coli 
- 25% ESBL-K.  pneumoniae 
No studies analyzing transmission dynamics of CPE 
from hospital to household setting  
Gottesman T et al., EID, 2008 
Wife with ALS  
July 2007:  
hospitalized (mec. ventilation) 
in Tel Aviv for 9 weeks.  
Urine positive for CP-Kp  
73-y old man 
June 2007: 
TURP with no documented CP-Kp 
Sept 2007:  
routine urine positive for CP-Kp   
Yusuf E et al., Microb Drug Res, 2016 
18-y old woman 
June 2014: 
ER with UTI 
ST405 OXA-48-Kp  
Family member 
Prostatectomy 
Postoperative UTI 
ST15 OXA-48-Kp  
? 
? 
1. Few studies analyzed CPE 
carriage in community 
(especially for healthy people) 
2. What kind of travel and where? 
Ny S et al., J Antimicrob Res, 2017 
No specific screening protocol for CPE 
Nov 2012 - Dec 2013 
2,134 subjects: 
People in community: 0% 
Valenza G et al., Antimicrob Agents Chemother, 2014 
No specific screening protocol for CPE 
Oct 2009 - Nov 2012 
3,344 subjects: 
healthy people but in contact with subjects 
with gastroenteritis: 
One OXA-244/CTX-M-14 E.  coli 
Reuland EA et al., J Antimicrob Chemother, 2016 
No specific screening protocol for CPE 
June 2011 - Nov 2011 
1,695 subjects: 
healthy people referring to 5 GPs: 
One OXA-48/CTX-M-14 E.  coli 
[man visiting Egypt/USA; parents from South Asia]   
Garrido A et al., Microb Drug Res, 2014 
No specific screening protocol for CPE 
Jan 2010 – June 2010 
2,508 subjects: 
1,796 outpatients with gastroenteritis: 0% 
712 inpatients: 0% 
Viau R et al., Clin Microbiol Rev, 2016 
Some selective plates may underestimate CPE carriage 
Nüesch-Inderbinen M et al., Ant Res & Infect Control, 2013 Zurfluh K et al., Ant Res & Infect Control, 2015 
Pires J et al., J Glob Antimicrob Res, 2018 
Apr 2012 - July 2012 
605 subjects: 
314 healthy staffs of a meat company: 0% 
291 primary care patients: 0% 
September 2014 
1,086 subjects: 
healthy staffs of a meat company: 
One OXA-48 E.  coli ST38 
July 2013 – November 2016 
337 subjects: 
164 healthy staffs of VetSuisse: =0% 
101 HIV+ subjects: 0% 
32 healthy staffs of Med Faculty: 0% 
40 healthy people not traveling: 0%   
May-June 2014 
501 subjects: 
320 outpatients: 0% 
181 inpatients: 4.4% 
[KPC-Kp, OXA-48-Kp, OXA-48-Koxy, VIM-Cfr]   
Rios E et al., J Med Microbiol, 2017 
Endemic areas: people in community with diarrhea 
Day KM et al., J App Microbiol, 2017 
Aug-Sept 2011 
152 subjects: 
people in community (≠ cities): 8.6% 
NDM-1 E. coli 
NDM-1 K. pneumoniae 
Local clusters 
Abdallah HM et al., Antimicrob Resist Infect Control, 2017 
No specific screening protocol for CPE 
Jan-May 2013 
100 subjects: 
people in community: 5% 
NDM K. pneumoniae 
(n=3) 
VIM K. pneumoniae 
(n=2) 
R.A. Bonomo et al., Clin Infect Dis, Apr 2018 
Travel and acquisition of CPE 
 
1. People receiving healthcare 
(emergency or medical tourism) 
 
2. Healthy people 
 
 
3. People with risk factors 
L. Armand-Lefèvre et al., Med Mal Infect, Feb 2018 
Jans B et al., Acta Clinica Belgica, 2015 
From January 2011 
CNSE + epidemiological data 
National Reference Center 
2012-2013:  
890 colonized/infected with CPE 
Travel history available for 566 (64%) 
66 (12%) out of 566 were travel-related  
(defined as “with or without hospitalization”)  
41/66 isolated at tertiary care hospitals (most in Brussels) 
Africa: 29 CPE (45%) Asia: 18 CPE (28%) Europe: 18 CPE (28%) 
Mostly OXA-48-like 
Nord Africa: Morocco, Tunisia, 
Egypt, Algeria, Senegal, Libya 
Mostly NDM 
 
Indian subcontinent: India, 
Pakistan, Vietnam 
KPC and OXA-48 
 
Turkey, Greece, Italy 
 
Receiving healthcare in  
endemic areas (transfer from) 
L. Armand-Lefèvre et al., Med Mal Infect, Feb 2018 
Very few studies reported acquired CPE among travelers  
[most studies did not use specific protocols to detect CPE in stools] 
Main risk factors for ESBL-E.  coli gut carriage:  
destination, digestive disorders and/or diarrhea, antibiotic intake  
E. coli: 88-100% 
K. pneumoniae: 0-8% 
Healthy travelers 
A: 30-y man; B: 66-y woman 
2009: visited India (New Delhi) 
No healthcare system (HCS) exposure 
Ciprofloxacin for enteritis 
At return admitted to the hospital 
A: urosepsis due to ESBL-E. coli 
B: perianal abscess Sau + ESBL-E. coli 
Rectal screening for A: K. pneumoniae 
NDM-1, CTX-M-28, CMY-6, DHA-1 
Rectal screening for B: K. pneumoniae 
NDM-1, CTX-M-15 
Strain A and B were unrelated 
At risk person 
66-y woman 
2009: lives in India (Darjeeling) 
No healthcare system (HCS) exposure 
Brest tumor 
Admitted in French Hospital 
Immediate cultures from tumor surface: 
NDM-1-producing E. coli 
Colistin-R 
ST131-type 
Ruppé E et al., Eurosurv., 2014 
VOYAG-R: Feb 2012 – March 2013  
574 French travelers of which  
57 who visited India (all negative) 
Detected 
Not detected 
Not provided 
1:  
~50-y healthy female 
Traveled alone 
17 days – April 2012 
Backpacker tourist 
No exposure to HCS or ABs 
2:  
~30-y healthy female 
Traveled with another person 
10 days – Nov 2012 
No exposure to HCS or ABs 
3:  
~30-y healthy female 
Traveled alone 
30 days – Jan 2013 
Backpacker + visited relatives 
No exposure to HCS or ABs 
Digestive disorders 
0.5% 
CPE 
 
5.3% 
India 
Reuland EA et al., Clin Microbiol Infect, 2016 
Vaccination Clinic, Amsterdam 
Apr 2012 – Apr 2013 
Africa, Asia, Latin America 
One OXA-48/CTX-M-9 E.  coli 
No specific screening 
protocol for CPE detection 
50-y female 
15 day visit to Egypt 
No exposure to HCS or ABs 
Traveler’s diarrhea 
Kuenzli E et al., BMC Infect Dis, 2014 
87% [3GC-R] 
0% 
December 2012 - October 2013 
170 healthy travelers negative at departure  
India: N=68 
One CPE 
NDM-1-producing E.  coli 
Overall 
0.6% 
CPE 
India 
1.5% 
CPE 
Univariate Multivariate 
Bernasconi OJ et al., Antimicrob Agents Chemother, 2016 Pires J et al., Front Microbiol, 2016 
Jan 2015 - Aug 2015 
53 travelers from Switzerland to India. Follow-up at 3, 6, 12, and 24 months 
No CPE carriers found 
May 2013 - Apr 2014 
225 healthy German volunteers 
traveling to 53 countries 
No CPE carriers found 
Lübbert C et al., Int J Med Micro, 2015 
Data about the transmission of CPE acquired by 
travelers to household members are needed  
63 HH members (negative at base-line) 
105 co-travelers (negative at return) 
who lived with travelers who acquired ESBL-E 
HH transmission 
(criteria: same ESBL group) 
3/63 (4.8%) 
10/105 (9.5%) 
7.7% 
STATISTICAL MODEL:  
probability of transmission = 12%  
Nov 2012 – Nov 2013 
2001 travelers  
and 168 household members 
(follow up at 3, 6, 12 mo)  
Van Hattem JM et al., Future Microbiol, 2016 
Possible 
Household 
Transmission 
COMBAT study 
Nov 2012 – Nov 2013 
2001 travelers and 215 non-traveling HH 
0.25% 
CPE * 
(n=500) 
All without  
HC exposure 
Diarrhea 
Diarrhea 
Antibiotic intake 
Ligation-mediated PCR 
 Most of the CPE found in community are healthcare-associated 
 but in endemic areas there is probably a high prevalence of CAI/C  
 Healthy travelers seem not significantly contributing to CPE importation 
 but those receiving healthcare are at high risk 
 Better epidemiological data about CPE (define CAI, COI, HAI) 
 not only laboratory-based studies 
 Adequate methods to screen for CPE gut carriage in community/travelers  
 We need studies focusing on:  
 CPE transmission in the household (esp. from discharged patients) 
 intestinal colonization with CPE in community (healthy people) 
 Better characterization of the CPE found in community/travelers (gut) 
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